US-based Takeda Oncology Company has announced positive results from a randomised Phase III trial of Velcade (bortezomib) as a treatment of multiple myeloma in patients who have had an autologous stem cell transplant.
The study involved 370 patients who were randomised to receive Velcade or a placebo.
The results showed that 45% of patients in the Velcade arm achieved a complete response or near complete response, compared to 35% of patients in the control group.
The drug, a proteasome inhibitor, led to significant improvements in response rates and progression-free survival.
The adverse effects seen in patients receiving Velcade include thrombocytopenia, neutropenia, peripheral neuropathy, neuralgia, pyrexia, leukopenia, dyspnea, insomnia and peripheral oedema.